Russian Study of the Effect of Continuous Positive Airway Pressure (CPAP) in Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00801671
Recruitment Status : Completed
First Posted : December 3, 2008
Last Update Posted : June 17, 2011
Information provided by:
Russian Cardiology Research and Production Center

Brief Summary:
The purpose of this study is to determine whether CPAP is effective in the treatment of systemic hypertension.

Condition or disease Intervention/treatment Phase
Obstructive Sleep Apnea Syndrome Hypertension Procedure: cPAP Phase 3

Detailed Description:

It is now well known that cardiovascular risks are increased in patients with obstructive sleep apnea syndrome (OSAS). Also a link has already been demonstrated between OSAS and hypertension.

Nowadays, the most efficient treatment of the OSAS is the continuous Positive Airway Pressure (cPAP). Several studies have also shown that cPAP could reduce arterial blood pressure in OSAS patients. But level of blood pressure (BP), drug treatment were not equal between groups and it`s difficult to single out independent role of cPAP.

Our study has the objective to compare the effects of cPAP on hypertension in OSAS patients. After 3-9 weeks of antihypertensive treatment (valsartan and amlodipine) those one who reached target level of BP will be randomized either in the group "treatment by cPAP" or in the group "treatment by cham-cPAP" for 3 weeks and then we`ll perform cross-over.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study of Independent Role of Continuous Positive Airway Pressure Therapy on Systemic Arterial Pressure in Patients With Sleep Apnea Syndrome and Arterial Hypertension
Study Start Date : September 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sleep Apnea
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1 Procedure: cPAP
After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
Sham Comparator: 2 Procedure: cPAP
After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)

Primary Outcome Measures :
  1. Ambulatory blood pressure monitoring over 24 hours, at inclusion visit (day=0), before cPAP (3-9 weeks) and after 3 weeks of cPAP. [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male/female over than 18 years old
  • patient with an obstructive sleep apnea (apnea-hypopnea index > or equal to 15)
  • patient with weak or moderate hypertension (140 <= SBP < 180 mmHg and 90 <= DBP < 110 mmHg)
  • negative pregnancy test
  • ambulatory patient
  • patient who have signed the informed consent form

Exclusion Criteria:

  • pregnant or nursing woman
  • woman who refuses to use contraceptive method
  • acute hepatic failure, biliary cirrhosis, cholestasis
  • clearance of Cockcroft < 30 ml/min/1.73m2
  • kaliemia >= 5.5 mmol/l
  • acute hypertension (SBP>= 180 mmHg and/or DBP >= 110 mmHg)
  • acute daytime sleepiness (Epworth rating scale > 15)
  • patient with a profession that is inconsistent with the continuous positive airway pressure (CPAP) treatment
  • known cardiovascular pathologies
  • contraindication to CPAP
  • allergy to valsartan and/or amlodipine
  • patient treated with lithium
  • patient on tutelle or curatelle
  • patient kept in detention, major protected by the law, hospitalized person patient currently participating in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00801671

Russian Federation
Russian Cardiologe Research and Production Complex
Moscow, Russian Federation, 121552
Sponsors and Collaborators
Russian Cardiology Research and Production Center
Principal Investigator: Alexandr Yu Litvin, MD Russian Cardiology Research and Production Center

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kseniya Orlowa, Weinmann Identifier: NCT00801671     History of Changes
Other Study ID Numbers: 1111
First Posted: December 3, 2008    Key Record Dates
Last Update Posted: June 17, 2011
Last Verified: June 2011

Keywords provided by Russian Cardiology Research and Production Center:
obstructive sleep apnea
obstructive sleep apnea syndrome
systemic hypertension
ambulatory blood pressure monitoring

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases